Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest Clinical Trials & Medical Discoveries

11 Jun, 2018, 07:00 BST ELEVATE Study Aims to Improve Selection Criteria and Outcomes for Patients with Severe Emphysema Treated with the PneumRx™ Endobronchial Coil System

Recruitment Begins in 7 European Countries BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd...


11 Jun, 2018, 06:26 BST Nordic Nanovector to Present Preclinical Data Demonstrating Betalutin® Reverses Resistance to Anti-CD20 Treatment in NHL Cells

Nordic Nanovector ASA (OSE: NANO) announces that a poster reporting the ability of Betalutin® (177Lu-lilotomab satetraxetan) to reverse resistance...


07 Jun, 2018, 22:00 BST Microbiotix presents new data at the ASM Microbe 2018 Conference

Seven presentations with data from multiple pipeline candidates including data from Microbiotix's innovative non-antibiotic programs targeting...


07 Jun, 2018, 07:00 BST 4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

4D pharma plc (AIM: DDDD) today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to...


07 Jun, 2018, 06:00 BST New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases

- Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral...


06 Jun, 2018, 13:00 BST Iterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic Sulopenem

In U.S. patients, quinolone non-susceptibility seen in over 20 per cent of isolates from the urinary tract, driven primarily by resistance in E....


06 Jun, 2018, 12:00 BST Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

–– Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile –– –– New Drug Application Anticipated...


05 Jun, 2018, 13:30 BST PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin

Abstract #8018 - The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE...


05 Jun, 2018, 13:00 BST IMI-PainCare: Public-private Partnership Tackles Major Challenges in the Care of Pain Patients

To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies,...


05 Jun, 2018, 13:00 BST Thermo Fisher Scientific supports the European STATIN trial to evaluate pravastatin in the potential prevention of preeclampsia

Research results suggest a preventive role of statins in the late-onset form of preeclampsia The STATIN trial (RandomiSed conTrolled trial...


05 Jun, 2018, 07:00 BST New England Journal of Medicine Publishes Cemiplimab Trial Results in Advanced Cutaneous Squamous Cell Carcinoma[1]

- Patients treated with cemiplimab experienced robust anti-tumour effects[1] - Data also presented today at the 2018 ASCO Annual...


04 Jun, 2018, 22:07 BST BERG Showcases New Clinical Data on BPM 31510 at ASCO 2018

BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today presented in a poster...


04 Jun, 2018, 13:30 BST PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

Abstract #8570 - The phase II basket trial, which began recruiting 15 patients with recurrent small-cell lung cancer, was increased to...


04 Jun, 2018, 13:00 BST The United States Patent and Trademark Office (USPTO) Awards Estar Medical a New Patent on its Innovative Platelet-Rich Plasma (PRP) Technology

Estar Technologies Ltd. ("Estar Medical", http://www.estar-medical.com), a global leader in autologous cell therapy technologies, announces that...


04 Jun, 2018, 06:17 BST Targovax to Present at Jefferies 2018 Global Healthcare Conference

Targovax ASA ("Targovax" or "the Company") (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid...


03 Jun, 2018, 22:00 BST Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of...


03 Jun, 2018, 22:00 BST Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to...


03 Jun, 2018, 19:14 BST BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib

BerGenBio ASA (OSE:BGBIO) announces that interim data from its Phase II clinical development programme with bemcentinib, a selective AXL inhibitor,...


03 Jun, 2018, 13:30 BST Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the...


01 Jun, 2018, 14:47 BST Cyxone Completes Acquisition of Drug Candidate Rabeximod

Cyxone AB (publ) announced today that the company has decided to complete the acquisition of drug candidate Rabeximod and issue approximately 1.9...


01 Jun, 2018, 13:00 BST Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- Updated subgroup analysis in 34 heavily pretreated patients with HER2-low-expressing metastatic breast cancer demonstrated a 50.0 percent...


01 Jun, 2018, 13:00 BST Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- First-in-human safety data presented from phase 1/2 study with U3-1402, an investigational and potential first-in-class HER3-targeting antibody...


01 Jun, 2018, 12:45 BST CHMP Adopts Positive Opinion for the Expansion of the Translarna™ (ataluren) Label to Include Patients as Young as 2 Years of Age

- European Commission ratification anticipated in coming months – - Approval of the Translarna annual re-assessment also recommended by CHMP -...


Most Viewed Clinical Trials & Medical Discoveries